Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations.
Amin Al Olama, A
Le Marchand, L
MetadataShow full item record
Identifying genetic variants with pleiotropic associations can uncover common pathways influencing multiple cancers. We took a two-stage approach to conduct genome-wide association studies for lung, ovary, breast, prostate, and colorectal cancer from the GAME-ON/GECCO Network (61,851 cases, 61,820 controls) to identify pleiotropic loci. Findings were replicated in independent association studies (55,789 cases, 330,490 controls). We identified a novel pleiotropic association at 1q22 involving breast and lung squamous cell carcinoma, with eQTL analysis showing an association with ADAM15/THBS3 gene expression in lung. We also identified a known breast cancer locus CASP8/ALS2CR12 associated with prostate cancer, a known cancer locus at CDKN2B-AS1 with different variants associated with lung adenocarcinoma and prostate cancer, and confirmed the associations of a breast BRCA2 locus with lung and serous ovarian cancer. This is the largest study to date examining pleiotropy across multiple cancer-associated loci, identifying common mechanisms of cancer development and progression. Cancer Res; 76(17); 5103-14. ©2016 AACR.
Version of record
Ovarian Cancer Association Consortium (OCAC)
Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON)
Colorectal Transdisciplinary (CORECT) Study
African American Breast Cancer Consortium (AABC) and African Ancestry Prostate Cancer Consortium (AAPC)
Functional Genetic Epidemiology
Molecular & Population Genetics
License start date
Cancer research, 2016, 76 (17), pp. 5103 - 5114
Showing items related by title, author, creator and subject.
Can routine data be used to support cancer clinical trials? A historical baseline on which to build: retrospective linkage of data from the TACT (CRUK 01/001) breast cancer trial and the National Cancer Data Repository. Kilburn, LS; Aresu, M; Banerji, J; Barrett-Lee, P; Ellis, P; Bliss, JM (2017-11-23)BACKGROUND: Randomised clinical trials (RCTs) are the gold standard for evaluating new cancer treatments. They are, however, expensive to conduct, particularly where long-term follow-up of participants is required. Tracking ...
Association of Breast Cancer Risk with Genetic Variants Showing Differential Allelic Expression: Identification of a Novel Breast Cancer Susceptibility Locus at 4q21 Swerdlow, A; Jones, M; garcia-closas, M